Photo of Thomas Keck

View Scopus Profile

Thomas Keck

  • 324 Citations
  • 12 h-Index
20062020
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Research Expertise:
Pharmacology | Neuroscience | Biochemistry

I am interested in developing new medications for neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, ADHD, pain, anxiety, and a particular interest in drug addiction. My lab works closely with medicinal chemists to design and test new drug-like molecules, combining molecular and behavioral pharmacology methods to evaluate the preclinical potential of new compounds designed to target the dopamine D4 receptor, the µ opioid receptor, and the trace amine-associated receptor 1, among others.

Honors and Awards:
2017 Maharaj Ticku Memorial Travel Fellowship for New Investigators Award, Behavior, Biology and Chemistry Conf.
2015 Frances R. Lax Faculty Development Award, Rowan University
2013 Mentoring Award for Fellows, NIDA-IRP, NIH
2013 Postdoctoral Mentor Award, NIH
2012 & 2013 Fellows’ Award for Research Excellence, NIH

Member of:
American Society for Pharmacology and Experimental Therapeutics https://www.aspet.org/
Pharmacology Society (Councilor) https://www.aspet.org/MAPS/
Philadelphia Chapter of the Society for Neuroscience http://pcsfn.com/

Education/Academic qualification

Doctor of Philosophy, doctorate

Fingerprint Dive into the research topics where Thomas Keck is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Dopamine D3 Receptors Medicine & Life Sciences
Ligands Medicine & Life Sciences
Metabotropic Glutamate 5 Receptor Medicine & Life Sciences
Substance-Related Disorders Medicine & Life Sciences
Dopamine Antagonists Medicine & Life Sciences
Dopamine D4 Receptors Medicine & Life Sciences
eticlopride Medicine & Life Sciences
Self Administration Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2020

Analgesia without Addiction: Synthesis and Development of Highly Selective Novel Analgesics

Keck, T.

New Jersey Health Foundation, Inc.

2/15/19 → 2/27/20

Project: Other project

Abuse liability and anti-addiction potential of the atypical mu opioid receptor agonist IBNtxA

Keck, T.

National Institutes of Health

4/1/17 → 3/31/19

Project: Research project

Research Output 2006 2019

  • 324 Citations
  • 12 h-Index
  • 20 Article
  • 1 Chapter

Cognitive and behavioral effects of brief seizures in mice

Batterman, A. I., DeChiara, J., Islam, A., Brenner, M. B., Fischer, B. D., Buono, R. J., Keck, T. & Ferraro, T., Sep 1 2019, In : Epilepsy and Behavior. 98, p. 249-257 9 p.

Research output: Contribution to journal › Article

Seizures
Epilepsy
Cognition
Locomotion
Post-Traumatic Epilepsy
1 Citation (Scopus)

Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy

Keck, T., Free, R. B., Day, M. M., Brown, S. L., Maddaluna, M. S., Fountain, G., Cooper, C., Fallon, B., Holmes, M., Stang, C. T., Burkhardt, R., Bonifazi, A., Ellenberger, M. P., Newman, A. H., Sibley, D. R., Wu, C. & Boateng, C. A., Apr 11 2019, In : Journal of Medicinal Chemistry. 62, 7, p. 3722-3740 19 p.

Research output: Contribution to journal › Article

Open Access
Dopamine D4 Receptors
Structure-Activity Relationship
Ligands
2-(3',4',5',6'-tetrahydro-2'H-(2,4') bipyridinyl-1'-yl)-N-m-tolyl-acetamide
Arrestin

Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia

Del Bello, F., Ambrosini, D., Bonifazi, A., Newman, A. H., Keck, T., Giannella, M., Giorgioni, G., Piergentili, A., Cappellacci, L., Cilia, A., Franchini, S. & Quaglia, W., May 15 2019, In : ACS Chemical Neuroscience. 10, 5, p. 2222-2228 7 p.

Research output: Contribution to journal › Article

Receptor, Serotonin, 5-HT1A
Parkinson Disease
Schizophrenia
Derivatives
Scaffolds
15 Citations (Scopus)

Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)

Kumar, V., Moritz, A. E., Keck, T., Bonifazi, A., Ellenberger, M. P., Sibley, C. D., Free, R. B., Shi, L., Lane, J. R., Sibley, D. R. & Newman, A. H., Feb 23 2017, In : Journal of Medicinal Chemistry. 60, 4, p. 1478-1494 17 p.

Research output: Contribution to journal › Article

Dopamine D3 Receptors
Pharmacology
Ligands
Pharmaceutical Preparations
1H-indole-2-carboxylic acid (4-(2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl)cyclohexyl)amide
8 Citations (Scopus)

The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1Areceptor over α1-adrenoceptor and D2-like receptor subtypes

Del Bello, F., Bonifazi, A., Giannella, M., Giorgioni, G., Piergentili, A., Petrelli, R., Cifani, C., Micioni Di Bonaventura, M. V., Keck, T., Mazzolari, A., Vistoli, G., Cilia, A., Poggesi, E., Matucci, R. & Quaglia, W., Jan 1 2017, In : European Journal of Medicinal Chemistry. 125, p. 233-244 12 p.

Research output: Contribution to journal › Article

Adrenergic Receptors
Amines
Ligands
Anxiety
Retrospective Studies